Business
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs\nCanada NewsWire\nCALGARY, July 21, 2016\n\n\n\nThe commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind.\n\n\n\nCALGARY, July 21, 2016 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) today announced that dosing has commenced in a Phase 1 PK study with lead drug candidate apabetalone (RVX-208) in patients with severe renal impairment. \n\nWhile the Company's Phase 3 BETonMACE trial, designed for high-risk cardiovascular disease patients with type 2 diabetes and low HDL is enrolling as planned, this Phase 1 trial has been initiated and designed in accordance with the Company's strategy to expand into new indications such as renal (chronic kidney disease) and orphan diseases with our lead candidate, apabetalone. This trial has the potential to create increased value for apabetalone in new high-risk patient segments which have shorter development paths to product registration and market adoption.\n\nThe primary objective of the Phase 1 study, based in New Zealand, is to determine if apabetalone treated patients with severe renal impairment have the same favorable PK traits as has been witnessed in previous apabetalone trials.  Results are expected in the second half of 2016, and if successful, will allow for more advanced renal impairment and dialysis trials to proceed. The study will also explore acute changes in biomarkers relevant to Bromodomain and Extra-Terminal (BET) inhibition in subjects with severe renal impairment. Two cohorts, each comprised of eight subjects, will be evaluated in the study. Cohort one will include subjects with end-stage renal disease (ESRD) not on dialysis, with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m2 while cohort two...